Zutectra: Uses, Dosage & Side Effects
Human hepatitis B immunoglobulin for the prevention of hepatitis B re-infection in adults after liver transplantation
Zutectra is a prescription medication containing human hepatitis B immunoglobulin (HBIg), specifically designed for subcutaneous self-administration to prevent hepatitis B virus (HBV) re-infection in adults who have undergone liver transplantation due to hepatitis B-induced liver failure. Derived from human blood plasma, Zutectra provides passive immunity through anti-hepatitis B surface antigen (anti-HBs) antibodies that neutralize HBV. It is supplied as a ready-to-use solution in pre-filled syringes (500 IU), typically administered weekly or every two weeks, with doses individually adjusted based on regular monitoring of anti-HBs antibody levels. Zutectra represents an important advancement in post-transplant HBV prophylaxis by allowing patients to self-inject at home rather than requiring intravenous infusions in a clinical setting.
Quick Facts: Zutectra
Key Takeaways
- Zutectra contains human hepatitis B immunoglobulin (anti-HBs antibodies) and is used exclusively to prevent HBV re-infection in adults who have undergone liver transplantation due to hepatitis B-induced liver failure.
- It is the first hepatitis B immunoglobulin specifically approved for subcutaneous self-administration at home, offering a significant quality-of-life improvement over intravenous alternatives that require hospital visits.
- Dosing is individualized (typically 500–1,000 IU weekly or every two weeks) and guided by regular monitoring of anti-HBs antibody trough levels to ensure adequate protection.
- As a plasma-derived product, Zutectra carries standard safety measures including rigorous donor screening and viral inactivation steps, though the risk of infection transmission cannot be completely eliminated.
- Zutectra must be stored refrigerated at 2–8 °C, must not be frozen, and should be injected immediately after removing the tip cap from the pre-filled syringe.
What Is Zutectra and What Is It Used For?
Zutectra contains antibodies against the hepatitis B virus, specifically anti-hepatitis B surface antigen (anti-HBs) immunoglobulins. These are the body's own natural defense proteins that protect against hepatitis B, a potentially life-threatening viral infection that attacks the liver. Hepatitis B virus infection can lead to chronic hepatitis, cirrhosis (scarring of the liver), liver failure, and hepatocellular carcinoma (liver cancer). When the disease progresses to end-stage liver failure, liver transplantation may be the only life-saving treatment option.
However, liver transplantation in patients with hepatitis B carries a significant risk of HBV re-infection of the new liver graft. Without prophylactic treatment, HBV recurrence rates after transplantation have historically been reported as high as 80–100%, often leading to rapid graft damage, accelerated cirrhosis of the transplanted liver, and graft loss. This is because HBV DNA persists in extrahepatic reservoirs (outside the liver) even after the diseased liver is removed, and the virus can readily infect the new transplanted organ.
To prevent this re-infection, hepatitis B immunoglobulin (HBIg) therapy is a cornerstone of post-transplant management. HBIg provides passive immunity by supplying pre-formed anti-HBs antibodies that bind to and neutralize circulating hepatitis B surface antigen (HBsAg), thereby preventing the virus from attaching to and infecting hepatocytes in the new liver. When combined with antiviral nucleos(t)ide analogues such as entecavir or tenofovir, HBIg-based prophylaxis has reduced HBV recurrence rates to below 5%, representing one of the most successful strategies in transplant medicine.
Traditionally, HBIg was only available as intravenous (IV) formulations, requiring patients to travel regularly to hospitals or infusion centers for treatment. This placed a considerable burden on patients, particularly in terms of time, travel, and impact on daily life. Zutectra was developed as the first hepatitis B immunoglobulin specifically designed for subcutaneous (under the skin) self-injection. Approved by the European Medicines Agency (EMA), Zutectra allows patients to administer their HBIg treatment at home after receiving proper training, significantly improving convenience and quality of life while maintaining effective protection against HBV re-infection.
Zutectra is indicated for use in adult patients who are at least one week post-liver transplantation. Treatment is initiated after the patient has been stabilized on intravenous HBIg in the immediate post-operative period, with anti-HBs antibody levels maintained at satisfactory levels. The transition from IV HBIg to subcutaneous Zutectra is made when the patient's condition is clinically stable and adequate antibody levels have been achieved.
The combination of hepatitis B immunoglobulin (such as Zutectra) with nucleos(t)ide analogue antiviral therapy is the international standard of care for preventing HBV recurrence after liver transplantation. This dual-prophylaxis approach has reduced HBV re-infection rates from approximately 80–100% (without treatment) to less than 5%, according to guidelines from EASL and AASLD. Zutectra's subcutaneous formulation allows this critical prophylaxis to be delivered conveniently in the home setting.
What Should You Know Before Taking Zutectra?
Contraindications
The primary contraindication to Zutectra use is hypersensitivity (allergy) to human immunoglobulins or to any of the other ingredients in the formulation (glycine and water for injections). A particularly important contraindication applies to patients with very rare cases of immunoglobulin A (IgA) deficiency who have developed antibodies against IgA in their blood. In these patients, administration of immunoglobulin products containing even trace amounts of IgA can trigger a severe, potentially life-threatening allergic reaction known as anaphylaxis.
An anaphylactic reaction can manifest as sudden wheezing and difficulty breathing, rapid heartbeat, swelling of the eyelids, face, lips, throat, or tongue, skin rash, or intense itching. If any of these signs occur, the injection must be stopped immediately and emergency medical attention sought without delay. Zutectra contains a maximum IgA content of 6,000 micrograms per milliliter, which is important information for patients with known or suspected IgA deficiency.
Zutectra is intended for subcutaneous injection only (under the skin). It must never be injected into a vein or blood vessel, as this can lead to allergic shock. Always follow the prescribed injection technique and ensure you have been properly trained before self-administering.
Warnings and Precautions
Before starting treatment with Zutectra, inform your doctor or healthcare professional about the following:
- IgA antibodies: If you are aware that you have antibodies against immunoglobulins of the IgA type in your blood, inform your doctor. This is very rare but may lead to allergic reactions, including sudden drops in blood pressure or anaphylactic shock.
- Previous immunoglobulin tolerance: You may be allergic to immunoglobulins without knowing it, even if you have previously tolerated treatment with human immunoglobulins. Particularly if you do not have sufficient amounts of IgA immunoglobulins in your blood, allergic reactions may occur.
- HBs antigen positive status: If you are HBs antigen positive (HBsAg positive), Zutectra will not be prescribed because the medication would provide no therapeutic benefit in this situation. Your doctor can explain the implications of this test result.
During and shortly after the first injection of Zutectra, you will be closely monitored by healthcare professionals to ensure that you do not experience a reaction. If an allergic reaction develops, the injection will be stopped immediately. After the initial observation period, and once a stable dose is established, patients can be trained to self-administer at home.
Your anti-HBs antibody levels will be monitored regularly through blood tests. This is essential to ensure that protective antibody levels are maintained and to guide any dose adjustments. The target anti-HBs trough level varies by clinical protocol but is typically maintained above 100 IU/L in most transplant centers, although some patients may require higher levels depending on their individual risk profile.
Effect on Blood Tests
Zutectra can affect the results of certain blood tests, particularly serological assays. The passively transferred antibodies present in the immunoglobulin preparation may interfere with specific blood serum tests and potentially lead to misleading results. It is important to inform your doctor and laboratory personnel that you are receiving Zutectra treatment before having any blood tests performed, so that test results can be interpreted correctly.
Safety of Plasma-Derived Products
Zutectra is manufactured from human blood plasma (the liquid portion of blood). When medicines are made from human blood or plasma, certain measures are taken to prevent infections being passed on to patients. These include careful selection of blood and plasma donors to exclude those who might carry infections, testing of each donation and plasma pool for signs of viruses and infections, and specific processing steps during manufacturing to inactivate or remove viruses.
Despite these measures, the possibility of transmitting infectious agents cannot be completely eliminated when medicines prepared from human blood or plasma are administered. This applies to any unknown or emerging viruses or other types of infections. The safety measures taken are considered effective against enveloped viruses such as human immunodeficiency virus (HIV), hepatitis B virus, and hepatitis C virus, as well as for the non-enveloped hepatitis A virus. The measures may have limited value against non-enveloped viruses such as parvovirus B19 (which causes fifth disease or erythema infectiosum).
Immunoglobulins like Zutectra have not been associated with hepatitis A or parvovirus B19 infections, possibly because the protective antibodies against these infections present in the product provide a shielding effect. It is strongly recommended that you record the batch number of Zutectra each time you receive a new supply and keep this information in a safe place such as your treatment diary.
Pregnancy and Breastfeeding
If you are pregnant, breastfeeding, think you may be pregnant, or are planning to become pregnant, consult your doctor or healthcare professional before using Zutectra. The safety of Zutectra during pregnancy and breastfeeding has not been established in controlled clinical trials. However, human immunoglobulins as a class have a long history of clinical use during pregnancy, and clinical experience suggests that no harmful effects on the course of pregnancy, the fetus, or the newborn are expected. Immunoglobulins are transferred across the placenta, particularly during the third trimester, and are also excreted in breast milk, potentially providing some passive protection to the infant.
Driving and Operating Machinery
Zutectra has no or negligible effect on the ability to drive or operate machinery. No impairment of these activities is expected based on the pharmacological properties and known safety profile of the medication.
How Does Zutectra Interact with Other Drugs?
As a human immunoglobulin preparation, Zutectra has a specific and clinically important interaction with certain types of vaccines. The passively transferred antibodies contained in immunoglobulin products can interfere with the immune response to live attenuated vaccines, potentially reducing their effectiveness. This is because the exogenous antibodies can neutralize the attenuated vaccine viruses before the recipient's immune system has a chance to mount its own protective response.
Vaccine Interactions
The following live attenuated vaccines may have reduced effectiveness if administered within 3 months of Zutectra treatment:
| Vaccine | Type | Recommended Waiting Period |
|---|---|---|
| Measles (MMR) | Live attenuated | At least 3 months after last Zutectra dose |
| Rubella | Live attenuated | At least 3 months after last Zutectra dose |
| Mumps | Live attenuated | At least 3 months after last Zutectra dose |
| Varicella (Chickenpox) | Live attenuated | At least 3 months after last Zutectra dose |
It is crucial to inform your doctor that you are receiving Zutectra treatment before any vaccination is scheduled. Your doctor will take this information into account when planning your vaccination schedule. Inactivated vaccines (such as influenza, pneumococcal, or COVID-19 mRNA vaccines) are generally not affected by immunoglobulin therapy and can be administered according to the standard schedule.
Antiviral Medications
Zutectra is typically used in combination with nucleos(t)ide analogue antiviral medications as part of a comprehensive HBV prophylaxis strategy after liver transplantation. Commonly co-prescribed antivirals include entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide. No clinically significant pharmacokinetic interactions have been identified between Zutectra and these antiviral agents, as they act through entirely different mechanisms. The immunoglobulin provides passive immunity through antibody-mediated neutralization, while the antivirals inhibit HBV DNA polymerase to suppress viral replication.
Immunosuppressant Medications
Liver transplant recipients typically receive lifelong immunosuppressive therapy to prevent organ rejection. Common immunosuppressant regimens include calcineurin inhibitors (tacrolimus or ciclosporin), mycophenolate mofetil, and corticosteroids. Zutectra can be safely administered alongside these immunosuppressive medications without dose adjustments. However, the immunosuppressed state of transplant patients may affect the overall immune response and should be considered in the context of the patient's complete medication regimen.
Always inform your doctor, pharmacist, and laboratory personnel that you are receiving Zutectra treatment. This is important for vaccination planning, blood test interpretation, and overall medication management. Keep an updated list of all your medications, including Zutectra, to share with all healthcare providers involved in your care.
What Is the Correct Dosage of Zutectra?
Zutectra is administered as a subcutaneous (under the skin) injection. Each pre-filled syringe contains 500 IU of human hepatitis B immunoglobulin in 1 mL of solution and is intended for single use only. The contents must not be injected into a blood vessel. The dose is individualized for each patient and may be adjusted based on clinical response and monitoring of antibody levels.
Adults
The recommended dose ranges from 500 IU up to 1,000 IU, administered once weekly or once every two weeks. In exceptional cases, the dose may be increased up to 1,500 IU. Your doctor will determine the appropriate dose and frequency based on your individual needs, taking into account your body weight, clinical status, and anti-HBs antibody trough levels.
| Parameter | Standard Dosing | Exceptional Cases |
|---|---|---|
| Dose per Administration | 500–1,000 IU | Up to 1,500 IU |
| Frequency | Once weekly or every 2 weeks | As directed by physician |
| Route | Subcutaneous injection | Subcutaneous injection |
| Monitoring | Regular anti-HBs trough levels | Regular anti-HBs trough levels |
Treatment with Zutectra is typically initiated after the patient has been stabilized on intravenous hepatitis B immunoglobulin during the early post-transplant period. The transition to subcutaneous Zutectra occurs when the patient's anti-HBs antibody levels are satisfactory and a stable dosing regimen has been established. Your doctor will closely monitor your condition during this transition and throughout the duration of treatment.
Self-Injection at Home
Once your antibody levels are satisfactory and you have established a stable dose, you or your caregiver may be trained to administer Zutectra injections at home. Self-administration is only appropriate after receiving proper training from your healthcare provider. It is strongly recommended that you use a treatment diary to document each injection, including the date, injection site, batch number, and any reactions observed.
Zutectra must be allowed to reach room temperature (approximately 23–27 °C) before use. The best injection sites are areas where the skin is loose and soft, such as the abdomen, upper arms, thighs, or buttocks. Avoid injecting into areas that are bruised, tender, hardened, scarred, or near joints, nerves, or bones. Rotate the injection site with each administration to prevent localized skin reactions.
Children and Adolescents
Zutectra is indicated for use in adults only. The safety and efficacy of Zutectra in children and adolescents under 18 years of age have not been established. Pediatric liver transplant recipients requiring HBV prophylaxis should be managed with alternative HBIg formulations and dosing regimens as directed by their transplant team.
Missed Dose
If you miss a scheduled dose of Zutectra, do not take a double dose to compensate. Contact your doctor to discuss how to manage the missed dose. Your doctor will advise you on the appropriate timing and dosage for your next injection. It is important to follow your doctor's instructions carefully to maintain protective antibody levels and prevent the risk of HBV re-infection.
Overdose
The consequences of overdose with Zutectra are not well characterized. If you have used more than the prescribed dose, contact your doctor, healthcare professional, or pharmacist immediately for advice. Given the nature of the product, significant toxicity from moderate overdose is unlikely, but medical assessment is recommended to monitor for any adverse effects and to adjust subsequent dosing as needed.
What Are the Side Effects of Zutectra?
Like all medicines, Zutectra can cause side effects, although not everyone who uses it will experience them. Most side effects observed with Zutectra have been mild to moderate in severity. As a human immunoglobulin product derived from blood plasma, the safety profile of Zutectra reflects both the specific characteristics of this product and the general class effects associated with immunoglobulin preparations.
Clinical trial data and post-marketing surveillance form the basis of the known safety profile. In clinical studies, the overall tolerability of subcutaneous Zutectra was favorable, with most adverse events being localized injection site reactions that resolved without specific treatment.
Stop the injection immediately and seek urgent medical care if you experience: skin rash, itching, wheezing or difficulty breathing, swelling of the eyelids, face, lips, throat, or tongue, low blood pressure, or rapid heartbeat. These may be signs of a severe allergic reaction (anaphylaxis).
Common
May affect up to 1 in 10 people
- Injection site pain
- Injection site hives (urticaria)
- Injection site hematoma (bruising)
- Injection site redness (erythema)
Uncommon
May affect up to 1 in 100 people
- Headache
- Upper abdominal pain
Rare (Reported Once Each)
Isolated reports from clinical trials and post-marketing
- Fatigue (exhaustion)
- High blood pressure (hypertension)
- Inflammation of the nose and throat (nasopharyngitis)
- Muscle spasms
- Allergic reactions (hypersensitivity)
- Abnormal heartbeat (palpitations), cardiac discomfort
- Itching (pruritus), skin rash
- Pain in the mouth and throat (oropharyngeal pain)
Class Effects of Human Immunoglobulins
Additional reactions reported with other immunoglobulin products
- Chills
- Headache
- Dizziness
- Fever
- Vomiting
- Mild allergic reactions
- Nausea
- Joint pain (arthralgia)
- Low blood pressure (hypotension)
- Moderate lower back pain
- Injection site reactions: swelling, tenderness, redness, hardening, local warmth, itching, bruising, and rash
Injection site reactions are the most frequently reported adverse events with Zutectra. These reactions are generally mild and transient, resolving on their own within hours to a few days without specific treatment. Rotating injection sites between administrations can help minimize the frequency and severity of these local reactions.
Hypersensitivity reactions to human immunoglobulins, while uncommon, represent the most clinically significant potential adverse effect. In very rare cases, severe anaphylactic reactions have been reported with immunoglobulin products, particularly in patients with IgA deficiency who have anti-IgA antibodies. This is why your first injection of Zutectra is administered under medical supervision with monitoring for at least the observation period following injection.
As a plasma-derived product, there is also a theoretical risk of transmission of infectious agents, although the rigorous donor screening and viral inactivation measures applied during manufacturing minimize this risk (see the section on plasma-derived product safety above). Patients are advised to record the batch number of each Zutectra supply and report any suspected adverse reactions to their healthcare provider.
It is important to report suspected side effects after the medicine has been authorized. This allows continued monitoring of the benefit-risk balance of the medicine. Healthcare professionals and patients are encouraged to report any suspected adverse reactions to their national pharmacovigilance authority.
How Should You Store Zutectra?
Proper storage of Zutectra is critical to maintaining the quality, safety, and efficacy of this biological product. As a human immunoglobulin preparation, the active protein is sensitive to temperature extremes, freezing, and light exposure, all of which can denature the antibodies and render the medication ineffective.
- Refrigerated storage: Store and transport Zutectra at 2–8 °C (36–46 °F). This is the required storage condition throughout the shelf life of the product.
- Do not freeze: Freezing will damage the immunoglobulin proteins and the product must be discarded if accidentally frozen.
- Protect from light: Keep the pre-filled syringe in the outer carton at all times to protect it from light exposure, which can degrade the protein.
- Immediate use after opening: The solution should be administered immediately after removing the tip cap from the pre-filled syringe. Do not store the opened syringe for later use.
- Visual inspection: Before each use, inspect the solution visually. It should be clear to opalescent, and colorless to pale yellow. Do not use Zutectra if the solution appears cloudy or contains particles.
- Expiration date: Do not use Zutectra after the expiration date stated on the outer carton, blister packaging, and pre-filled syringe after "EXP." The expiration date refers to the last day of the stated month.
- Keep out of reach of children: Store Zutectra in a secure location away from children.
- Proper disposal: When the injection is complete, immediately place all needles, syringes, and empty glass containers into a sharps disposal container. Do not dispose of medicines in household waste or via wastewater. Ask your pharmacist how to dispose of medicines that are no longer needed.
When traveling with Zutectra, ensure the medication is transported in an insulated cool bag with an ice pack or cold pack to maintain the required temperature range of 2–8 °C. Avoid exposing the product to excessive heat or direct sunlight. If traveling by air, carry Zutectra in your hand luggage rather than checked baggage, as temperatures in the cargo hold may fall below freezing.
What Does Zutectra Contain?
Understanding the composition of Zutectra is particularly important given that it is derived from human blood plasma. Below is a detailed breakdown of the product's contents.
Active Ingredient
The active substance is human hepatitis B immunoglobulin, present at a concentration of 500 IU per milliliter. Each pre-filled syringe contains 1 mL of solution, delivering a dose of 500 IU. The immunoglobulin is derived from the pooled plasma of donors with high levels of anti-hepatitis B surface antigen (anti-HBs) antibodies.
Zutectra contains 150 mg/mL of human plasma protein, of which at least 96% is immunoglobulin G (IgG). The IgG provides the anti-HBs antibodies that are responsible for the therapeutic effect. The maximum content of immunoglobulin A (IgA) is 6,000 micrograms per milliliter, which is relevant for patients with IgA deficiency (see Contraindications).
Inactive Ingredients (Excipients)
| Ingredient | Role | Notes |
|---|---|---|
| Human hepatitis B immunoglobulin | Active substance (anti-HBs antibodies) | 500 IU per syringe |
| Glycine | Stabilizer / amino acid excipient | Protects protein structure and stability |
| Water for injections | Solvent | Pharmaceutical-grade water |
Appearance and Packaging
Zutectra is supplied as a solution for injection in pre-filled syringes. The solution may vary in appearance from clear to opalescent and from colorless to pale yellow. Each pre-filled syringe contains 1 mL of solution at 500 IU/mL. Zutectra is available in a pack size of 5 pre-filled syringes in a blister package. Each syringe is for single use only.
Zutectra is manufactured by Biotest Pharma GmbH, Landsteinerstrasse 5, D-63303 Dreieich, Germany. The product is authorized and distributed in multiple European countries through various local pharmaceutical representatives. For up-to-date information about this medicine, consult the European Medicines Agency (EMA) website or your national medicines regulatory authority.
Frequently Asked Questions About Zutectra
The key difference is the route of administration. Zutectra is specifically formulated for subcutaneous injection (under the skin), which can be self-administered at home after proper training. Traditional intravenous (IV) hepatitis B immunoglobulin must be administered in a clinical setting by healthcare professionals, requiring regular hospital visits. Both provide the same type of protection through anti-HBs antibodies, but Zutectra offers significantly greater convenience and improved quality of life for patients requiring long-term HBV prophylaxis after liver transplantation.
In most clinical protocols, hepatitis B immunoglobulin prophylaxis is continued indefinitely after liver transplantation, as the risk of HBV re-infection persists for as long as the transplanted liver is in place. Some transplant centers have explored strategies to simplify prophylaxis over time, such as transitioning to antiviral monotherapy in carefully selected low-risk patients. However, any changes to your prophylactic regimen should only be made by your transplant hepatologist based on individual risk assessment and monitoring of HBV markers.
Yes, you can travel with Zutectra, but you need to maintain proper storage conditions. Transport the medication in an insulated cool bag with a cold pack to keep it at 2–8 °C. When flying, carry Zutectra in your hand luggage (not checked baggage) as cargo hold temperatures can drop below freezing. Carry a letter from your doctor explaining that you need to carry injectable medication, as well as a copy of your prescription. Plan ahead to ensure you have sufficient supplies for the duration of your trip.
Because Zutectra is made from human blood plasma, recording the batch number is an important safety measure. In the very unlikely event that a batch is found to be associated with any safety concern, the batch numbers allow traceability so that affected patients can be identified and appropriate measures taken. Record the date and batch number (found on the packaging after "Batch" or "Lot") each time you start a new supply, and keep this information in your treatment diary in a safe place.
Injecting Zutectra into a blood vessel (intravenous injection) is specifically warned against, as it may lead to allergic shock. If you suspect that you have accidentally injected into a blood vessel, stop the injection immediately and seek medical attention right away. Watch for any signs of an allergic reaction such as difficulty breathing, facial swelling, rapid heartbeat, or feeling faint. To avoid accidental intravascular injection, always follow the proper subcutaneous injection technique as taught by your healthcare provider and inject into the fat layer between the skin and muscle.
While controlled clinical trials have not been conducted specifically with Zutectra in pregnant women, human immunoglobulins as a class have a long history of use during pregnancy. Clinical experience suggests that no harmful effects on the course of pregnancy, the fetus, or the newborn are expected. However, given the specialized nature of post-transplant care, any decisions regarding Zutectra use during pregnancy should be made in close consultation with both your transplant team and your obstetrician, weighing the critical need for HBV prophylaxis against any theoretical concerns.
References
- European Medicines Agency (EMA). Zutectra Summary of Product Characteristics. Last updated February 2024. Available at: EMA - Zutectra EPAR.
- European Association for the Study of the Liver (EASL). EASL Clinical Practice Guidelines on the Management of Hepatitis B Virus Infection. Journal of Hepatology. 2024;80(2):431–507.
- Terrault NA, et al. Update on Prevention, Diagnosis, and Treatment of Chronic Hepatitis B: AASLD 2018 Hepatitis B Guidance. Hepatology. 2018;67(4):1560–1599. Updated 2023.
- World Health Organization (WHO). Global Hepatitis Report 2024. Geneva: WHO; 2024.
- Cholongitas E, Papatheodoridis GV. High genetic barrier nucleos(t)ide analogue(s) for prophylaxis from hepatitis B virus recurrence after liver transplantation: a systematic review. American Journal of Transplantation. 2013;13(2):353–362.
- Marzano A, et al. Prophylaxis and treatment of hepatitis B in immunocompromised patients. Digestive and Liver Disease. 2007;39(5):397–408.
- Beckebaum S, et al. Efficacy of subcutaneous hepatitis B immunoglobulin (Zutectra) in the prevention of hepatitis B virus recurrence after liver transplantation. Annals of Transplantation. 2018;23:25–34.
- British National Formulary (BNF). Hepatitis B Immunoglobulin. National Institute for Health and Care Excellence (NICE). Updated 2025.
Medical Editorial Team
Medical Content
Written by iMedic Medical Editorial Team – specialists in hepatology, transplant medicine, and clinical pharmacology
Medical Review
Reviewed by iMedic Medical Review Board according to EASL, AASLD, and WHO guidelines
Evidence Standard
Evidence Level 1A – Based on EMA-approved product information, systematic reviews, and international clinical practice guidelines
Independence
No pharmaceutical funding or commercial sponsorship. All content is editorially independent.
Last medical review: . This article is reviewed and updated regularly to reflect the latest medical evidence and guidelines. For questions about this content, contact our editorial team.